安杰思收盘下跌5.36%，滚动市盈率22.16倍，总市值65.35亿元

Core Viewpoint - Anjias's stock closed at 80.7 yuan, down 5.36%, with a rolling PE ratio of 22.16 times, and a total market value of 6.535 billion yuan [1] Company Summary - Anjias specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, primarily focusing on GI, EMR/ESD, and ERCP diagnostic series [1] - The company has received several government honors, including the "Zhejiang Province Export Brand" title and the "Quality Award" from the Linping District People's Government [1] - For the first half of 2025, Anjias reported revenue of 302 million yuan, a year-on-year increase of 14.56%, and a net profit of 126 million yuan, maintaining a gross profit margin of 70.21% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Anjias at 49th place within the industry [1][2] - As of the latest report, 10 institutions hold shares in Anjias, including 5 other entities, 4 funds, and 1 brokerage, totaling 17.6384 million shares with a market value of 1.143 billion yuan [1]